• Twitter
  • LinkedIn
  • RSS
InterveXion Therapeutics
  • About Us
    • Overview
    • Management Team
    • Financial Conflict of Interest
  • Research & Development
    • Anti-Methamphetamine Products
    • Intellectual Property
    • Methamphetamine Use Disorder
  • Publications
    • Recent Publications
    • Anti-Methamphetamine Monoclonal Antibody
    • METH Vaccine
    • Anti-Phencyclidine Monoclonal Antibody
    • Review Articles
  • Contact Us
  • News
Select Page

Methamphetamine impairs IgG1-mediated phagocytosis and killing of Cryptococcus neoformans by J774.16 macrophage- and NR-9640-microglia-like cells | Infection and Immunity

Dec 10, 2018 | METH in the news

Our findings suggest that METH abrogates immune cellular and molecular functions and may be deadly to phagocytic cells, which may result in increased susceptibility of users to acquire infectious diseases. Source: Methamphetamine impairs IgG1-mediated phagocytosis and...

Increase in Methamphetamine Use by Iowans (11/26/18)

Dec 3, 2018 | METH in the news

Meth is now the second most reported drug by adults at admission to treatment, moving ahead of marijuana for the first time. Source: Increase in Methamphetamine Use by Iowans...

U.S. GAO – Adolescent and Young Adult Substance Use: Federal Grants for Prevention, Treatment, and Recovery Services and for Research

Dec 3, 2018 | METH in the news

For National #MethAwarenessDay, read and listen to how federal grants are targeted to prevent and treat substance abuse among adolescents and young adults. Source: U.S. GAO – Adolescent and Young Adult Substance Use: Federal Grants for Prevention, Treatment, and...

Recent Posts

  • InterveXion Therapeutics Awarded Federal Grant to Fund Phase 2 Study for Methamphetamine Use Disorder
  • InterveXion Enrolls First Patient in Meth-OD, a Phase 2 Study of IXT-m200 in Methamphetamine Overdose
  • InterveXion Announces Positive Data in Phase 2 Study of IXT-m200 in Participants with Methamphetamine Use Disorder
  • InterveXion Therapeutics Awarded Federal Grant to Fund Phase 2 Study for Methamphetamine Overdose
  • InterveXion Therapeutics Awarded Federal Grant to Fund Ongoing Development Program for IXT-m200 for Methamphetamine Use Disorder

Recent Comments

    Archives

    • October 2021
    • September 2021
    • April 2021
    • October 2020
    • May 2020
    • February 2020
    • January 2020
    • December 2019
    • November 2019
    • August 2019
    • July 2019
    • June 2019
    • May 2019
    • April 2019
    • February 2019
    • January 2019
    • December 2018
    • November 2018
    • May 2018
    • January 2018
    • October 2017
    • June 2017
    • January 2016
    • January 2015
    • November 2014
    • February 2014
    • August 2013
    • July 2013
    • December 2012
    • November 2012
    • May 2012
    • April 2012
    • July 2011
    • April 2011
    • October 2009
    • September 2009
    • March 2005
    • January 2005

    Categories

    • Anti-METH antibody, IXT-m200
    • Anti-METH Vaccine
    • Anti-PCP ch-mAb6B5
    • General News
    • Grants
    • METH in the news
    • Uncategorized

    Meta

    • Log in
    • Entries RSS
    • Comments RSS
    • WordPress.org
    • Twitter
    • LinkedIn
    • RSS
    © 2017 Intervexion